BNA 2023 | Why target vascular dysfunction in Alzheimer’s disease?

Silvia Anderle, PhD, University College London, discusses the rationale for prioritizing vascular dysfunction as a therapeutic target in Alzheimer’s disease (AD). Current investigational therapies for AD primarily focus on targeting toxic proteins such as amyloid-beta (Aβ) and tau. However, recent research has revealed that vascular damage occurs even before the accumulation of Aβ and is exacerbated by its build up. Dr Anderle suggests that the ultimate goal is to discover therapeutics that can improve vascular function, improving blood flow and oxygen delivery, as well as tackling toxic protein accumulation. This interview took place at The BNA 2023 International Festival of Neuroscience in Brighton, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.